Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say, ‘Every new day should be unwrapped like a precious gift.’ While you tug on the ribbon, we will be brewing yet another cup of stimulation — and invite you to join us. Meanwhile, here are some items of interest to help you on your journey today. We hope all goes well and that you remain safe. And one more thing — do keep in touch. …

The U.S. government pause on use of the Johnson & Johnson (JNJ) Covid-19 vaccine is unlikely to be lifted for at least another week or 10 days, after an independent panel of experts declined to vote on whether usage should resume, STAT says. Federal health officials urged states to halt usage on Tuesday to seek advice from the panel on some rare but serious clotting problems seen in some people. One person has died. Many panel members said they did not have enough information to estimate benefits and risks, or to restrict use to certain age groups.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]